TY - JOUR
T1 - Coagulation factor Xa signaling: the link between coagulation and inflammatory bowel disease?
AU - Borensztajn, Keren
AU - Peppelenbosch, Maikel P.
AU - Spek, C. Arnold
PY - 2009
Y1 - 2009
N2 - Inflammatory bowel disease (IBD) is characterized by activation of the coagulation cascade and it has long been suspected that coagulation is an essential component of this still largely idiopathic group of diseases. The realization that coagulation factors are not only passive mediators in the propagation of coagulation, but also actively engage different cell types by activating proteinase-activated receptors (PARs) has provided mechanistic insight into how coagulation cascade propagation might participate in the progression of IBD. The emergence of PAR2 as a key player in the progression of IBD has focused attention on its agonist, coagulation factor Xa (FXa). Recent findings on FXa and PAR2 link the coagulation cascade to the progression of IBD. Here, we propose that FXa-induced PAR2 activation has an important role in orchestrating intestinal inflammatory and fibroproliferative responses, and that PAR2 might provide a novel therapeutic target for the management of IBD
AB - Inflammatory bowel disease (IBD) is characterized by activation of the coagulation cascade and it has long been suspected that coagulation is an essential component of this still largely idiopathic group of diseases. The realization that coagulation factors are not only passive mediators in the propagation of coagulation, but also actively engage different cell types by activating proteinase-activated receptors (PARs) has provided mechanistic insight into how coagulation cascade propagation might participate in the progression of IBD. The emergence of PAR2 as a key player in the progression of IBD has focused attention on its agonist, coagulation factor Xa (FXa). Recent findings on FXa and PAR2 link the coagulation cascade to the progression of IBD. Here, we propose that FXa-induced PAR2 activation has an important role in orchestrating intestinal inflammatory and fibroproliferative responses, and that PAR2 might provide a novel therapeutic target for the management of IBD
U2 - https://doi.org/10.1016/j.tips.2008.10.007
DO - https://doi.org/10.1016/j.tips.2008.10.007
M3 - Review article
C2 - 19058861
SN - 0165-6147
VL - 30
SP - 8
EP - 16
JO - Trends in pharmacological sciences
JF - Trends in pharmacological sciences
IS - 1
ER -